The drug acts as a prostacyclin receptor agonist, which is a fairly crowded class with several approved oral, intravenous or inhaled therapies. However, United hopes that, as a once-daily oral therapy ...

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...

While Global Strategy sets the initial direction, true agility is sustained through a 360-degree loop that prioritises ...

Specifically, the CHMP has backed conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for children ...

Atrium is led by Kathleen Gallagher, who was chief programme officer at Avidity before it was acquired by Novartis and will ...

Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple sclerosis (RMS), and is now being prepared for regulatory filings.

uniQure held a Type A meeting with the FDA at the end of January and, in a statement released today, said the agency "cannot agree that data from the Phase I/II studies, compared to an external ...

Recent transactions make clear that large pharmaceutical companies now view rare disease as a core area for sustained growth, rather than episodic deal-making. BioMarin’s acquisition of Amicus ...

However, traditional clinical trial designs are often ill-suited for rare disease research with common challenges including ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...

The IPO, which saw 25 million shares sold at $16, in the middle of the $15 to $17 range predicted by the company, continues a ...

Boehringer Ingelheim has become the second company to get a product approved under the FDA's national priority voucher ...